UnionStrong® adheres to the integration of medicine and engineering, fostering collaborative innovation across academia, industry, and research. It actively contributes to national and provincial-level key research projects, positioning itself as a pivotal force in transforming scientific achievements and integrating innovative resources. Guided by its mission of "AI Empowers Healthcare, Technology Protects Life", the company aims to revolutionize key aspects of cerebrovascular disease diagnosis and treatment through "AI+therapy" and "AI+decision-mak_x0002_ing".

In the therapeutic domain, UnionStrong® has developed the AI-driven next-generation "intelligent and automatic catheter navigation" neurointerventional surgery solution—an AI solution,a world-Pioneered, China-Originated disruptive innovation. This system comprises three components: 1.Class III AI Software (UKnow® Intracranial Aneurysm Surgery Planning Software, NMPA Medical Device Regis_x0002_tration Certificate No. 20223211346); 2.UMate™ Shape Automatic Shaping Terminal (China Compulsory Certification No.2023180901040086); 3.UMate™ Mandrel Neuro-Intervention Consumable (BJ Medical Device Registration Certificate No. 20242030003). The core AI software holds China's first Class III Innovative Medical Device Certificate for AI Therapy, certified as " International Leading Level" by the National Science and Technology Achievement Appraisal. It has won the National Patent Award, been recognized as a national patent-intensive product, and officially obtained the Indone_x0002_sia Medical Device Registration Certificate.This AI solution has won multiple prestigious awards, including:Grand Prize in Medical and Health Category at the " Maker Beijing 2024" Entrepreneurship Contest;Pioneer Technology Award in the 2023 " Science and Technology Innovation China" (STIC) Rankings;Gold Medal in the Medical Track at the 2021 World Artificial Intelligence Conference (WAIC) Best Practices of Applied Algorithms (BPAA). Currently, the solution is listed in:Beijing's First (Set) Major Technical Equipment Catalogue;Beijing's Innovative Technologies, Products, and Services Catalogue;Zhongguancun Innovative Medical Device Catalogue.

in the decision-making domain, the UKnow® Risk Intracranial Aneurysm Assessment Software — another China-origi_x0002_nated, globally novel product — became China's first " AI+Decision" software to enter the Special Review Process for Innovative Medical Devices in 2023. Leveraging multi-dimensional, multi-modal, and full-scale patient data, it supports critical clinical decision-making and treatment evaluation. The product was shortlisted in the 2022 AI Medical Device Innovation Task jointly organized by the Ministry of Industry and Information Technology (MIIT) and National Medical Products Administration (NMPA), and was later honored as an Outstanding Unit in the same initiative in 2024.

The company's proprietary AI technologies are extensively cited in the 2024 editions of China's clinical guidelines, including:Clinical Management Guidelines for Unruptured Intracranial Aneurysms (2024); Clinical Management Guidelines for Ruptured Intracranial Aneurysms (2024);Chinese Guideline for Imaging Interpretation of Intracranial Aneurysms (2024). These guidelines highlight the application of UnionStrong®'s AI technologies in aneurysm screening, reconstruc_x0002_tion, measurement, stability assessment, treatment, and follow-up. Notably, the AI-driven personalized microcath_x0002_eter shaping technology has been validated and preliminarily applied in clinical practice, receiving a Grade I Recommendation (Strongly Recommended) with Level B Evidence (Moderate Certainty). This marks a significant milestone in the comprehensive integration of AI into intracranial aneurysm diagnosis and treatment, demonstrat_x0002_ing both clinical validation and practical breakthroughs.